Hospital Drug Discount Transparency Bill Faces Heavy ‘Lift’ In Congress
This article was originally published in The Pink Sheet Daily
Executive Summary
But biopharma industry can help drive reform of 340B discounts by emphasizing how it might improve pricing, Rep. Chris Collins, R-NY, suggests.
You may also be interested in...
340B Reform May Return To Capitol Hill: Hearings Will Play To New HRSA Leadership
Rep. Chris Collins (R-NY) plans to introduced a bill to reform the 340B drug discount program in the coming weeks, and says he has a commitment from the House Energy & Commerce Committee leadership to consider the bill in hearings over the summer; that in turn may help shape HRSA’s oversight of the program in the Trump Administration.
340B “Mega-Guidance” Delayed To December (Or Beyond)
HRSA official stresses importance “good faith” by manufacturers and purchasers to assure program integrity while key definitions remain in limbo.
340B Purchases To Hit 8% Of Outpatient Brand Drug Sales In 2019 – White Paper
Berkeley Research Group finds fault with the oft-cited idea that 340B accounts for only 2% of total drug sales. Meanwhile, 340B hospitals issue their own data showing they serve lower-income populations than other hospitals.